<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881413</url>
  </required_header>
  <id_info>
    <org_study_id>OMCP98004</org_study_id>
    <nct_id>NCT00881413</nct_id>
  </id_info>
  <brief_title>Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding</brief_title>
  <official_title>Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lotung Poh-Ai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tomorrow Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lotung Poh-Ai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the clinical effectiveness of intravenous esomeprazole
      and pantoprazole in preventing recurrent bleeding in the patients with high-risk bleeding
      peptic ulcers after successful standard endoscopic hemostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic hemostasis and proton pump inhibitor (PPI) constitute the cornerstone in the
      management of peptic ulcer bleeding (PUB), which remains a prevalent disorder associated with
      substantial morbidity and mortality. Clinical effectiveness of PPI in the management of
      patients with PUB has been established by compelling evidence derived from a number of
      randomized trials. However, whether different PPIs are equally effective has not been
      investigated. Esomeprazole, the S-isomer of omeprazole, may achieve faster, more profound and
      steady acid suppression than other PPIs, but it remains undetermined whether the superiority
      of pharmacologic efficacy may be translated into advantages in clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    problems in funding
  </why_stopped>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrent bleeding within 14 days of enrollment</measure>
    <time_frame>14 days after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of blood transfusion</measure>
    <time_frame>14 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgery</measure>
    <time_frame>14 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>14 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding-related mortality</measure>
    <time_frame>14 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>probably one month after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose esomeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose pantoprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months</description>
    <arm_group_label>Esomeprazole</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months</description>
    <arm_group_label>Pantoprazole</arm_group_label>
    <other_name>Pantoloc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged more than 18 years

          -  undergo emergent endoscopy within 24 hours of presentation

          -  have peptic ulcers in the gastroesophageal junction, stomach, or duodenum

          -  high-risk stigmata of peptic ulcers: Forrest classification IA~IIB

          -  endoscopic hemostasis by thermocoagulation or clip placement

        Exclusion Criteria:

          -  pregnant or lactating

          -  written informed consent not obtained

          -  initial endoscopic hemostasis fail

          -  bleeding tendency (platelet count &lt; 50×109/L, prolonged prothrombin time for more than
             3 seconds, or were taking anticoagulants)

          -  PPI use within 14 days of enrollment

          -  comorbid with severe hepatic or renal insufficiency (serum total bilirubin more than 5
             mg/dL, serum creatinine more than 5 mg/dL, or under dialysis)

          -  bleeding gastric cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hwai-Jeng Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotung Poh-Ai Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <reference>
    <citation>Sung JJ, Barkun A, Kuipers EJ, Mössner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T; Peptic Ulcer Bleed Study Group. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 7;150(7):455-64. Epub 2009 Feb 16.</citation>
    <PMID>19221370</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <name_title>Professor Hwai-Jeng Lin</name_title>
    <organization>Lotung Poh-Ai Hospital</organization>
  </responsible_party>
  <keyword>Peptic ulcer bleeding</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <keyword>Esomeprazole</keyword>
  <keyword>Pantoprazole</keyword>
  <keyword>Recurrent bleeding</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

